In addition, pre-clinical research presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany this summer, demonstrated that omacetaxine kills human CML stem cells that are known to be insensitive to TKIs.
ChemGenex Pharmaceuticals Limited (ASX:CXS), announced today that the results of pre-clinical research that demonstrated that omacetaxine kills model human leukemic stem cells were presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Sunday.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that positive, updated data from its phase 2/3 clinical trial study of omacetaxine in chronic myeloid leukemia (CML) patients with resistance to multiple tyrosine kinase inhibitors (TKIs) was presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Saturday.
ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
Longer Survival Than Previously Demonstrated COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG) today announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID([R]) (lenalidomide) plus dexamethasone significantly increased their survival rates.
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG) today announced that preliminary data from an international study of single agent REVLIMID (lenalidomide) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) were presented at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
